A Review on Uses of Various Nanoparticlesin the Treatment of Rheumatoid Arthritis

Authors

  • Shriram Bairagi Department of Pharmaceutical Chemistry, Ideal College of Pharmacy and Research, Kalyan, Mumbai, India
  • Smita Takarkhede Department of Pharmaceutical Chemistry, Ideal College of Pharmacy and Research, Kalyan, Mumbai, India
  • Jagruti Dighe Department of Pharmaceutical Chemistry, Ideal College of Pharmacy and Research, Kalyan, Mumbai, India
  • Dhaneshwari Gangurde Department of Pharmaceutical Chemistry, Ideal College of Pharmacy and Research, Kalyan, Mumbai, India

DOI:

https://doi.org/10.22270/ajprd.v10i1.1073

Keywords:

Autoimmune Disease, Rheumatoid Arthritis, Nanoparticles, Nanotechnology, Inflammation, Drug Delivery System,

Abstract

Rheumatoid arthritis (RA) is a most common autoimmune (auto-self: immune-immunity system). It is inflammatory in nature. If generally causes bone and cartilage destruction. Itaffect on joint clinical manifestationsof arthritis various from patient to patient. Now, new field comes into existence called use of nanoparticles and nanotechnology. It improves the pharmacokinetic as well as pharmacodynamics of rheumatoid arthritis drugs. Nanoparticles act on site of inflammation and delivery of therapeutic agent to that site. It also increases specificity of drugs and decrease side effects. These review summarize the current therapeutic strategies for rheumatoid arthritis. Nanotechnology or nanoparticles used in treatment of rheumatoid arthritis. Mostly focus on application of nanoparticles in treatment of rheumatoid arthritis.

 

Downloads

Download data is not yet available.

Author Biographies

Shriram Bairagi, Department of Pharmaceutical Chemistry, Ideal College of Pharmacy and Research, Kalyan, Mumbai, India

Department of Pharmaceutical Chemistry, Ideal College of Pharmacy and Research, Kalyan, Mumbai, India

Smita Takarkhede, Department of Pharmaceutical Chemistry, Ideal College of Pharmacy and Research, Kalyan, Mumbai, India

Department of Pharmaceutical Chemistry, Ideal College of Pharmacy and Research, Kalyan, Mumbai, India

Jagruti Dighe, Department of Pharmaceutical Chemistry, Ideal College of Pharmacy and Research, Kalyan, Mumbai, India

Department of Pharmaceutical Chemistry, Ideal College of Pharmacy and Research, Kalyan, Mumbai, India

Dhaneshwari Gangurde, Department of Pharmaceutical Chemistry, Ideal College of Pharmacy and Research, Kalyan, Mumbai, India

Department of Pharmaceutical Chemistry, Ideal College of Pharmacy and Research, Kalyan, Mumbai, India

References

1. Mcinnes I.B., G. Schett–The Pathogenesis of Rheumatoid Arthritis, J Med. 2011; (365): 2205-2219.
2. Firestein G.S, Evolving Concepts of Rheumatoid Arthritis; Nature. 2003; (423): 356-361.
3. Tanaka. Y, Ann. Rheum. Dis. 2013;(ii):124-127.
4. Hoes JN, Jacobs JW, Buttgereit F,Bijlsma JW. Current View of Glucocorticoids Co-therapy with DMARDs in Rheumatoid Arthritis Nat Rev Rheumatol. 2010; 693-702 [PubMed] [Google Scholar].
5. Gupta R. B,Kompella U. B, Nanoparticle Technology Drug Delivery, Taylor and Francis Grup New York. 2006; 4-6, 13-16.
6. Ain Q, Zeeshan M., Khans, Ali H, J Biomed. Mater. Res., Part A. 2019; (107):2595-2600.
7. Bordat A.,Boissenot T, Nicolas J. and Tsapis N, Adv. Drug Delivery Rev. 2019;(138): 167-162.
8. Wang Q. Jiang J, Chen. W., Jiang. H, Zhang Z And Sun X, J. Controlled Release. 2016;(230): 64-72.
9. Qindeel. M, Khan. D, Ahemed, N, Khan S, Asim R, ACS Nano.2020;(14): 4662-4681.
10. Jain. S, Tran. T.H, Amiji M., Biomaterials. 2015;(61): 162-177.
11. Wang W. Feng S and Zheng C|, Int.J.Pharm. 2016; (513): 387-392.
12. Malam. Y, Loizidou. M and Seifalian A. M, Trends Pharmacol. Sci. 2009; (30): 592-599.
13. Mastrotto F,Brazzale. C, Bellato. F, Demartin. S, Grange G, Mahmoudzadeh M, Magarkar A, Bunker A, Salmaso S and P. Caliceti, Mol. Pharm. 2020; (17): 1444.
14. Shimizu T, Abu Lila A, Fujitan R, Awata M., Kawanishi, Hashimoto Y, Okuhira K, Ishima Y, Ishida T, Eur.J.Pharm, Biopharm. 2018;(127): 142-149.
15. Edmundson M.C., M. Capeness and L. Horsfall, Nat. Biotechnol. 2014; (31): 572-578.
16. Kim. J, Kim. H. Y, Song. S. Y, Go. S. H, Sohn. H. S, Baik. S, Soh M, Kim. K, Kim. C. H, Lee. N, Kim. B. S and Hyeon. T., ACS Nano. 2019; (13): 3206-3217.
17. Li. H, Guo. H, Lei. L, Xu. L, Feng. Y, Ke. J, Fang. W, Song. H, Xu. C, Yu. C and X. Long, Adv. Mater. 2019; (31): e1904535.
18. Dalli. J, Montero-Melendez, Norling. L, Yin. X, Hinds. C, Haskard. D, Mayr. M and Perretti. M, Mol. Cell. Proteomics. 2013; (12): 2205-2219.
19. Li. J, Zhen. X, Lyu. Y, Jiang. Y, Huang. J and Pu. K, ACS Nano. 2018; (12): 8520-8530.
20. Berckmans. R, Nieuwland. R, Kraan. M, Schaap. M, Pots. D, Smeets. T, Sturk. A and Tak. P, Arthritis Res, Ther. 2005;(7): R536-R544.
21. Tavasolian. F, Moghaddam. A, Rohani. F, Abdollahi. E, Janzamin. E, Momtazi-Borojeni. A, Moallem. S, Jamialahmadi. T and Sahebkar. A, Autoimmun. Rev. 2020; 19
22. Liu. L, Hu. F, Wang. H, Wu. X, Eltahan. A. S, Stanford. S, Bottini. N, Xiao. H, Bottini. M, Guo. W and Liang. X. J, ACS Nano. 2019; (13): 5036-5048 .
23. Liu L., Hu F., Wang H, Wu. X, Eltahan A. S, Stanford S, Bottini N, Xiao H, Bottini M., Guo W and Liang X.J, ACS Nano. 2019; (13): 5036-5048.
24. HornosCarnerio M.F and Barbosa F, Jr, J. Toxicol. Environ. Health, PartB. 2016; (19):129-148.
25. Arima H. Yamashita S, Mori Y, Hayashi Y , Motoyama K, Hattori K, Takeuchi T, Jono H, Ando Y, Hirayama F, and Uekama K, J. Controlled Release. 2010; (146):106-117.

Published

2022-02-15

How to Cite

Bairagi, S., Takarkhede, S., Dighe, J., & Gangurde, D. (2022). A Review on Uses of Various Nanoparticlesin the Treatment of Rheumatoid Arthritis. Asian Journal of Pharmaceutical Research and Development, 10(1), 38–44. https://doi.org/10.22270/ajprd.v10i1.1073

Issue

Vol. 10 No. 1 (2022): Vol 10 No 1 (2022): Vol 10 No 1 (2022): Volume 10 Issue 1 Jan - Feb. 2022

Section

Review Articles

AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.

Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).